Business

• Disney names parks boss Josh D’Amaro as its next CEO to succeed Bob Iger, effective March 18 - Disney has named Josh D'Amaro, chairman of Disney Experiences, as its next CEO, succeeding Bob Iger and clinching a closely watched succession race at the Mouse House.
• Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial - The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
• Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook - The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
• Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms - Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.
• PepsiCo earnings beat estimates as drinks sales pick up around the world - PepsiCo reported fourth-quarter earnings and revenue that topped Wall Street's estimates.
• Rare earth stocks jump after Trump launches $12 billion critical minerals stockpile - The moves come shortly after President Donald Trump announced the establishment of a U.S. critical mineral reserve.
• Disney signals its next CEO will take over a company with strong momentum - Disney CEO Bob Iger touted the company's growth in its last three years as the company prepares to announce his successor.
• Disney beats Wall Street expectations propelled by theme parks and streaming - In the background of Disney's earnings report on Monday is the question of who will be named the successor to CEO Bob Iger. 
• How to trade the market spiral as investors dump gold, silver and oil - Analysts flagged U.S. President Donald Trump’s nomination for the next chair of the Federal Reserve as a key trigger to the latest market downturn.
• From Clawdbot to Moltbot to OpenClaw: Meet the AI agent driving buzz and fear globally - OpenClaw, formerly known as Clawdbot and Moltbot, has generated massive buzz from Silicon Valley to Beijing due to its impressive capabilities, but also its quirks and risks.